Welcome to our dedicated page for Arrowhead Pharma SEC filings (Ticker: ARWR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
When a single RNAi therapy can pivot on a line item buried deep in the footnotes, Arrowhead Pharmaceuticals� SEC documents often feel like a molecular biology textbook. R&D expenses for the TRIM� delivery platform, milestone payments from licensing partners, and trial safety data are scattered across hundreds of pages. If you have ever asked, “How do I find Arrowhead Pharmaceuticals insider trading Form 4 transactions?� you already know the challenge.
Stock Titan solves it. Our AI reads every Arrowhead Pharmaceuticals quarterly earnings report 10-Q filing the moment it hits EDGAR, highlights fresh cash-burn metrics, and flags clinical milestone language. It pulls executive stock sales from Arrowhead Pharmaceuticals Form 4 insider transactions real-time, summarizes 8-K material events explained in plain English, and converts the 300-page annual report into an Arrowhead Pharmaceuticals annual report 10-K simplified digest. You also get quick answers to natural questions like “understanding Arrowhead Pharmaceuticals SEC documents with AI� or “Arrowhead Pharmaceuticals proxy statement executive compensation.�
Here’s what you can do in one dashboard:
- Track Arrowhead Pharmaceuticals executive stock transactions Form 4 alongside pipeline catalysts
- Compare R&D spend across periods with Arrowhead Pharmaceuticals earnings report filing analysis
- Receive instant alerts for every Arrowhead Pharmaceuticals 8-K material event
Stop combing through PDFs. Stock Titan’s expert analysis turns Arrowhead Pharmaceuticals SEC filings explained simply into actionable insight—so you can focus on whether the next gene-silencing breakthrough just moved closer to market.
Daniel Joseph Apel, Chief Financial Officer of Arrowhead Pharmaceuticals (ARWR), reported direct beneficial ownership of 101,200 shares of common stock. The filing specifies that this total includes 100,000 restricted stock units that will vest over four years, disclosed on an initial Form 3.
State Street Corporation filed a Schedule 13G reporting beneficial ownership of 6,371,056 shares of Arrowhead Pharmaceuticals Inc. common stock, representing 4.6% of the class as of the event date 06/30/2025. The filing is signed on behalf of State Street by Elizabeth Schaefer, Senior Vice President and Chief Accounting Officer, on 08/08/2025.
The statement shows no sole voting or dispositive power (0 shares) and records shared voting power of 5,952,902 shares and shared dispositive power of 6,371,056 shares. Item 7 identifies State Street advisory and funds entities as affiliated managers (for example, SSGA Funds Management, Inc.; State Street Global Advisors Europe Limited). The filing does not indicate a group filing or identify any other person with >5% ownership.
FAQ
What is the current stock price of Arrowhead Pharma (ARWR)?
What is the market cap of Arrowhead Pharma (ARWR)?
